These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29211877)

  • 21. MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY.
    Cui JJ; Wang LY; Tan ZR; Zhou HH; Zhan X; Yin JY
    Mass Spectrom Rev; 2020 Sep; 39(5-6):523-552. PubMed ID: 31904155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring and pharmacokinetics/pharmacodynamics of antibiotics as useful tools for translational research and personalized medicine.
    Navarro AS
    Clin Pharmacokinet; 2015 Sep; 54(9):885-6. PubMed ID: 25940824
    [No Abstract]   [Full Text] [Related]  

  • 23. Toward Personalized Cancer Treatment: From Diagnostics to Therapy Monitoring in Miniaturized Electrohydrodynamic Systems.
    Khondakar KR; Dey S; Wuethrich A; Sina AA; Trau M
    Acc Chem Res; 2019 Aug; 52(8):2113-2123. PubMed ID: 31293158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Right Dose, Right Now: Customized Drug Dosing in the Critically Ill.
    Roberts JA; Kumar A; Lipman J
    Crit Care Med; 2017 Feb; 45(2):331-336. PubMed ID: 28098629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial stewardship.
    Doron S; Davidson LE
    Mayo Clin Proc; 2011 Nov; 86(11):1113-23. PubMed ID: 22033257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial stewardship programs.
    Leuthner KD; Doern GV
    J Clin Microbiol; 2013 Dec; 51(12):3916-20. PubMed ID: 23926165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mathematics of drug dose individualization should be built with random-effects linear models.
    Diaz FJ; de Leon J
    Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
    Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
    J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety.
    Lee DK; Chang VY; Kee T; Ho CM; Ho D
    SLAS Technol; 2017 Jun; 22(3):276-288. PubMed ID: 27920397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial stewardship programs: how to start and steer a successful program.
    Drew RH
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S18-23. PubMed ID: 19236137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
    Holford NH; Buclin T
    Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-time monitoring of antimicrobial use density to reduce antimicrobial resistance through the promotion of antimicrobial heterogeneity in a haematology/oncology unit.
    Murata S; Mushino T; Hosoi H; Kuriyama K; Kurimoto M; Watanuki J; Nishikawa A; Sonoki T; Nakakuma H; Hanaoka N
    J Antimicrob Chemother; 2015 Sep; 70(9):2661-4. PubMed ID: 26071518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Appropriate use of antimicrobial agents: challenges and strategies for improvement.
    Niederman MS
    Crit Care Med; 2003 Feb; 31(2):608-16. PubMed ID: 12576973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy.
    Levy Hara G; Kanj SS; Pagani L; Abbo L; Endimiani A; Wertheim HF; Amábile-Cuevas C; Tattevin P; Mehtar S; Lopes Cardoso F; Unal S; Gould I
    Int J Antimicrob Agents; 2016 Sep; 48(3):239-46. PubMed ID: 27502752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
    Heil EL; Johnson JK
    J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of JAC to antimicrobial stewardship.
    Johnson AP
    J Antimicrob Chemother; 2016 Nov; 71(11):3001-3007. PubMed ID: 27880718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic policy.
    Gyssens IC
    Int J Antimicrob Agents; 2011 Dec; 38 Suppl():11-20. PubMed ID: 22018989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial stewardship.
    Tamma PD; Cosgrove SE
    Infect Dis Clin North Am; 2011 Mar; 25(1):245-60. PubMed ID: 21316003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic monitoring of antimicrobial agents.
    Begg EJ; Barclay ML; Kirkpatrick CM
    Br J Clin Pharmacol; 2001; 52 Suppl 1(Suppl 1):35S-43S. PubMed ID: 11564051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.